

2016 BIO World Congress Workshops + IP Symposium Program

**Sunday, April 17, 2016
2:30 PM – 4:30 PM
Location: Room 10**

Growing a Billion Ton Bioeconomy in the United States



Sponsored by:

Join the Biomass Research and Development Board Operations Committee at a Bioeconomy Listening Session at the upcoming 2016 BIO World Congress on Industrial Biotechnology. Conference attendees are invited to join the listening session, on "Growing a Billion Ton Bioeconomy in the United States," held April 17th at 2:30-4:30 PM to provide thoughts, comments and ask questions on the potential to grow the national bioeconomy. Listening session hosts plan to solicit input from participants on what opportunities may exist and what challenges need to be confronted in order to achieve a focused and successful bioeconomy vision for the United States. This Listening Session will be run using *ThinkTank Collaborative Technology* to gather input from participants. Attendees will be required to bring their own personal devices capable of accessing the internet and entering responses.

In preparation for the session, it is also strongly encouraged that attendees review the recently released Federal Activities Report on the Bioeconomy: http://www.biomassboard.gov/pdfs/farb_2_18_16.pdf. The Federal Activities Report on the Bioeconomy is a product of an interagency collaboration under the Biomass Research and Development (R&D) Board, which includes members from the federal agencies, such as, United States Departments of Energy, Agriculture, Interior, Transportation, Defense, and the Environmental Protection Agency, the National Science Foundation, and the Office of Science and Technology Policy. The report has been prepared to emphasize the significant potential for a stronger United States bioeconomy through the production and use of biofuels, renewable chemicals, biobased products, and biopower. The report also delves into the wide-ranging, federally funded activities that are currently helping to bolster the bioeconomy.

Moderators—Todd Campbell, United States Department of Agriculture, Policy Advisor, Energy and Bioeconomy; Harry Baumes, United States Department of Agriculture, Director, Office of Energy Policy and New Uses, Office of the Chief Economist

**Tuesday, April 19, 2016
10:30 AM - 12:00 PM
Location: Room 5A**

What Investors Require When Making A Bioeconomy Investment?

Sponsored by:

SternBrothers&Co.

**FAEGRE BAKER
DANIELS**

 **KILPATRICK
TOWNSEND**

ATTORNEYS AT LAW

This panel will focus on a series of crucial decisions potential investors consider regarding bioeconomy technology companies and/or their projects when determining whether or not to invest. Some of these considerations include, but are not limited to, the following: (i) areas of technology will they entertain—renewable chemicals, biobased products or biofuels; (ii) levels of technology risk from those that are acceptable to ones that are insurmountable and how acceptable risks must be mitigated; (iii) strength and type of IP and how it is protected or not; (iv) strength and experience of management teams—have they successfully stood up similar technologies and made good use of prior investment dollars; (v) types—common or preferred equity/venture debt/etc. and expected percentage returns on investments; (vi) expected controlling or minority ownership positions including the expectation of one or more board seats; (vii) timing and amounts of funding available in one or more rounds of development; and (viii) timing and types of acceptable exits—are they in for follow-on rounds or not—do they expect an IPO after certain milestones are met or other exit strategies. The financially experienced moderators will control a fast-paced discussion among the panelists of these and other issues that must be considered. Audience participation is strongly encouraged.

Moderators—John May, Managing Director, Stern Brothers; John Kirkwood, Partner, Faegre Baker Daniels LLP; Mark J. Riedy, Partner, Kilpatrick Townsend & Stockton LLP

Panelists

1. Tom Huot, Managing Director, Vantage Point Capital Partners
2. Josko Bobanovic, Managing Partner, Sofinnova Partners
3. Mario Portela, Managing Director, Texas Pacific Group

**Tuesday, April 19
10:30am- 12:00pm
Location: Room 5B**

Bridging the Gap: Building a Young Scientist Pipeline for a More Diverse Science Future



Sponsored by:

Like many industries, the life sciences will face a critical shortage of talent in the coming decades, especially with respect to women and under-represented minorities. This workshop session will involve all attendees working together in small groups to brainstorm possible solutions for how the industrial biotech industry can better promote, educate and inspire youth to pursue the life sciences as a career.

Moderators— Adam Monroe, President, Novozymes Americas

Panelists

1. Debbie Yaver, Director, Productions Strain Technology, Novozymes
2. Larry P. Walker, co-editor-in-chief, Industrial Biotechnology Journal

**Tuesday, April 19
10:30am- 12:00pm
Location: Room 4**

BASF and Avantium Joint Venture: global market and technology leadership on FDCA and PEF



Sponsored by: avantium

BASF and Avantium have announced their intend to establish a JV for the production and commercialization of FDCA and PEF. FDCA is one of the most promising biobased building blocks with multiple applications. Avantium has developed a proprietary catalytic process to convert biomass into FDCA economically. The main application of FDCA is PEF, a polyester with superior properties over polyesters like PET, offering novel packaging opportunities. By joining forces with BASF, the #1 chemical company, the companies combine the Avantium technology with the manufacturing and engineering know how and scale of BASF, which puts them on a pathway towards global market and technology leadership on FDCA and PEF. During the session the speakers will discuss their strategy to attain the global leadership position in PEF and FDCA from the perspective of Avantium, the Renewables strategy of the BASF Chemical Intermediates division, and the PEF market opportunity.

Moderators— Jim Lane, Biofuels Digest

Panelists

1. Tom van Aken, CEO, Avantium
2. Nathan Kemeling, Director Business Development YXY, Avantium
3. Cordula Mock-Knoblach, Director Renewables & Sustainability, Global New Business Development Operating Division Intermediates, BASF

2016 BIO World Congress IP Symposium

**Wednesday, April 20
8:30am – 10:00am**

Assessing and Preserving Value in Biotechnology Intellectual Property

ROBINS  KAPLAN_{LLP}

Sponsored by:

Not all intellectual property is created equal. From IP creation, to perfection of rights, to commercialization, care must be taken to ensure that the enforceability of IP is not compromised. This panel will provide guidance on maintaining IP value while conducting the business of using and commercializing important technologies.

Moderators— Matthew McFarlane, Robins Kaplan LLP

Panelists

1. Reena R. Desai, Synthetic Genomics, Inc.
2. David Dodds, Dodds & Associates
3. Sherry Roberg-Perez, Robins Kaplan LLP

**Wednesday, April 20
10:30am – 12:00pm**

Procuring Patents for Industrial Biotechnology Innovations

Sponsored by: 

This panel will focus on the special challenges in securing patents in the industrial biotechnology area, primarily using 3D bioprinting and biofabrication innovations as representative examples to highlight the issues in view of recent developments in patent law.

We will provide an overview of emerging trends in industrial biotechnology innovations including the 3D bioprinting and biofabrication innovations of our panelists, and then turn to

the threshold question of patent eligibility for such innovations under the current interpretations and applications of 35 USC 101. In particular, we will discuss the current status of Section 101 rejections during prosecution, and strategies to overcome or avoid the rejections such as claim drafting strategies and other patent prosecution strategies.

We will also discuss strategies to deal with other challenges that the panelists and other applicants in the industrial biotechnology areas face during patent prosecution that arise from the technology, such as enablement and written description.

Moderators— Barbara Rudolph, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP

Panelists

1. Kai Rajan, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
2. Hans Sauer, Biotechnology Innovation Organization
3. Len Smith, Heliae